AstraZeneca announced disappointing results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody combination, for the prevention of symptomatic COVID-19 in participants recently exposed to SARS-CoV-2, and real-world data for the effectiveness of its COVID-19 vaccine against the Delta variant of SARS-CoV-2:
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.